Compare Amylx Pharmaceuticals Inc (AMLX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Prospect Capital Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $24.01 (market cap $2.64B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Amylx Pharmaceuticals Inc is far larger — about 2.3× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.93% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PSEC | |
|---|---|---|
Market Cap | $2.64B | $1.14B |
Sector | Health | Financials |
52-Week High | $24.19 | $3.05 |
52-Week Low | $7.82 | $2.11 |
Enterprise Value | $2.39B | — |
Dividend Yield | — | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
PSEC trades at $2.29, down 1.72% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. The stock carries a low P/B of 0.39 and has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $469.92 million in 2025. Recent news includes a dividend increase announcement and the sale of portfolio company Valley Electric for $328 million.
The outlook is cautious; while the deep discount to book value and consistent dividend payments offer income appeal, significant negative revenue and net income margins, alongside a divided analyst consensus, highlight substantial business and market risks. The primary opportunity lies in a potential valuation recovery if operational performance improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
